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Abstract Allogeneic stemcell transplantation is used in the
treatment of younger patients with severe hematological
diseases, especially hematological malignancies, and acute
graft versus host disease (GVHD) is then an important
immune-mediated posttransplant complication. Several risk
factors for acute GVHD have been identified, including
pretransplant factors that possibly influence the posttranspant
course through their effects on host immunocompetent cells.
Metabolic regulation is important for immunoregulation, and
we therefore investigated whether the pretransplant meta-
bolic status of allotransplant recipients was associated with
later acute GVHD. In our population-based study we inves-
tigated the systemic (serum) metabolic profile for 86 con-
secutive allotransplant recipients. The samples were
collected before start of the pretransplant conditioning ther-
apy. Patients who developed later acute GVHD especially
showed altered pretransplant amino acid metabolism,
including (1) altered metabolism of immunoregulatory
branched chain amino acids (leucine, isoleucine and valine);
and (2) altered levels of potentially proinflammatory tyrosine
metabolites (p-cresol sulphate, 3-phenylpropionate) formed
by the gastrointestinal microbial flora. However, isobutyryl-
carnitine and propyonylcarnitine levels were also altered; the
carnitines are important for the transport of fatty acids and
may also be important for the release of immunoregulatory
cytokines in allotransplant recipients. These metabolic
alterations were associated with an ongoing pretransplant
acute phase reaction or early hematopoietic/immune recon-
stitution. Thus, allotransplant recipients developing acute
GVHD showed altered preconditioning/pretransplant levels
of several immunoregulatory metabolites. Our hypothesis is
that these metabolites alter or activate recipient immuno-
competent cells and thereby enhance or initiate anti-recipient
immune reactivity.
Keywords Metabolomics  Allogeneic stem cell
transplantation  Acute leukemia  Acute graft versus host
disease
1 Introduction
Allogeneic hematopoietic stem cell transplantation (allo-
SCT) represents an effective therapeutic strategy in
younger patients with a variety of severe hematological
disorders. The strong antileukemic effect of allo-SCT is
due to the intensive conditioning therapy, nonspecific graft
versus host reactivity and specific graft versus leukemia
(GVL) effects (Kersey 2010). However, these beneficial
effects are counteracted by the risk of severe and poten-
tially lethal posttransplant complications including serious
infections, immune-mediated acute and chronic graft-ver-
sus-host disease (GVHD) and treatment-related organ
toxicity (Gooley et al. 2010). The decision to recommend
allo-SCT therefore thus has to be individualized and based
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on the expected long-term disease-free survival with con-
ventional chemotherapy alone versus the risk of relapse
and the risk of treatment-related mortality/morbidity after
allogeneic transplantation. Several strategies based on
pretransplant prognostic factors of long-term survival have
been suggested (Gratwohl 2012; Servais et al. 2014; Sorror
2009). However, these systems are mainly based on clini-
cal factors and may be improved if additional biological
factors could be incorporated, e.g. the pretransplant serum
profiles of immunoregulatory cytokines that differ between
allotransplant recipients with and without posttransplant
acute GVHD (Reikvam et al. 2012a, b, 2013).
Metabolomic profiling, or metabolomics, is the study of
low molecular weight compounds in biological fluids and
metabolites can then be defined as non-peptide molecules
often representing end products of cellular activity.
Therefore, changes in metabolite concentrations reveal the
range of biochemical effects induced by diseases and/or
therapeutic intervention. During the last years metabolomic
profiling has become possible through the development of
new technologies, and studies in patients with acute mye-
loid leukemia (AML) have described both a specific
metabolic profile associated with mutations in the isocitrate
dehydrogenases 1 and 2 genes (IDH 1/2) (Wang et al.
2013) as well as a distinct glucose metabolism signature
associated with resistance to cytarabine and decreased
survival (Chen et al. 2014).
The overall nutritional/metabolic status as well as the
levels of several single metabolites is important for
immunoregulation (Tvedt et al. 2016). In this context we
have investigated whether pretransplant metabolic profiles
reflects a risk of posttranspant acute GVHD, and we
describe associations between the pretransplant metabolic
profile and the posttransplant clinical course.
2 Materials and methods
2.1 Patients
The study was approved by the local Ethics Committee
(Regional Ethics Committee III, University of Bergen,
Norway) and samples collected after written informed
consent. The study included 86 consecutively allotrans-
planted adult patients (54 men and 32 women; median age
45 years with range 15–69 years) from a defined geo-
graphic area (Norwegian Health Regions III, IV and V)
transplanted with a family donor. The decision to perform
an allotransplantation was taken by the Norwegian Advi-
sory Board for Stem Cell Transplantation and based on
national guidelines. Thus, our study is population-based
and includes an unselected and consecutive group of well-
characterized patients.
The clinical characteristics of the patient are given in
Table 1 and Supplementary Fig. 1. Most patients received
GVHD prophylaxis with cyclosporine A and methotrexate,
only two patients received cyclosporine A alone. Patients
were transplanted with granulocyte colony-stimulating
factor (G-CSF) mobilized peripheral blood stem cells
derived from HLA-matched family donors (aplastic anemia
patients received bone marrow grafts). Neutrophil recon-
stitution was defined as three consecutive days with neu-
trophil counts of at least 0.2 9 109/L, and platelet
reconstitution as stable platelet counts exceeding 20 9 109/
L for at least three consecutive days. All patients were
carefully examined for and classified with regard to
comorbidity according to Sorror et al. (2009); none of the
patients had liver or renal disease and the overall comor-
bidity score was low (1 or 0). Sinusoidal obstruction syn-
drome was not diagnosed in any patient.
All samples were collected before start of conditioning
therapy (median 19 days before, range 3–56 days). GVHD
was diagnosed according to generally accepted criteria
(Filipovich 2008). Briefly, the diagnosis of acute GVHD
was generally based on careful clinical evaluation and
additional skin biopsies for patients with skin involvement
alone. The diagnosis of acute GVHD for the patients with
liver and/or gastrointestinal involvement was also based on
careful clinical evaluation and additional biopsies (in-
cluding eight with skin biopsies and five with biopsies from
the gastrointestinal tract) except for one patient with liver
involvement for whom acute GVHD was a clinical
diagnosis.
2.2 Sample preparation, analysis of metabolite
serum levels and bioinformatical analyses
All venous blood samples were collected into sterile plastic
tubes (BD Vacutainer SSTTM Serum Separation Tubes,
Becton-Dickenson; Franklin Lakes, NJ, USA) and allowed
to coagulate for 120 min at room temperature (18 C)
before centrifugation (300 g for 10 min) and serum col-
lection. All samples were immediately frozen at -70 C
until analyzed.
Metabolomic profiling analysis of all samples was car-
ried out in collaboration with Metabolon as described
previously (Evans et al. 2014). Each sample was acces-
sioned into the Metabolon LIMS system and was assigned
by the LIMS a unique identifier, and was used to track all
sample handling, tasks, results, etc. The samples (and all
derived aliquots) were tracked by the LIMS system. Sam-
ples were prepared using the automated MicroLab STAR
system from Hamilton Company. A recovery standard was
added prior to the first step in the extraction process for QC
purposes. To remove protein, dissociate small molecules
bound to protein or trapped in the precipitated protein
12 Page 2 of 11 H. Reikvam et al.
123
matrix, and to recover chemically diverse metabolites,
proteins were precipitated with methanol under vigorous
shaking for 2 min, followed by centrifugation. The
resulting extract was divided into four fractions: one for
analysis by UPLC-MS/MS with positive ion mode elec-
trospray ionization, one for analysis by UPLC-MS/MS with
Table 1 Demographical,
clinical and laboratory data for
the 86 patients included in the
study
Patient characteristics Observation
Demographic data and disease history
Gender (numbers)
Male/female 54/32
Age (years, median and range) 45 (15–69)
Height (cm, median and range) 176 (149–197)
Weight (kg, median and range) 71 (42–133)















Bu ? Cy 69
ATG ? Cy 4
TBI ? Cy 2
TBI ? Eto 1
Flu ? Bu 9
Flu ? Cy 1
Acute GVHD (numbers) 31 out of 77 evaluable patients
Reconstitution (day posttransplant)
Neutrophils (day; median and range)
[0.2 9 109/L (3 consecutive days) 16 (6–52)
Platelets (day; median and range)
[20 9 109/L (3 consecutive days) 15 (9–33)
Baseline pretransplant status
WBC (median and range) 3.7 (0.5–14.1) 9 109/L
Hb (median and range) 10.4 (7.8–14.1) g/dL
Platelets (median and range) 141 (7–721) 9 109/L
CRP (median and range) 5 (1–120) mg/L
LDH (median and range) 187 (92–1655) UI/dL
Values are unless otherwise stated given as median and range in parenthesis. Height and weight were
registered at the start of conditioning therapy
BMI body mass index, AML acute myelogenous leukemia, MDS myelodysplastic syndrome, ALL acute
lymphoblastic leukemia, CML chronic myelogneous leukemia, CMML chronic myelomonocytic leukemia,
CLL chronic lymfocytic leukemia, PMF primary myelofibrosis, AA aplastic anemia, CR complete remis-
sion, Bu busulphan, Cy cyclophosphamide, ATG anti-thymoglobulin, TBI total body irradiation, Eto eto-
poside, Flu fludarabine, GVHD graft versus host disease, WBC white blood cell count, Hb hemoglobin,
CRP C-reactive protein, LDH lactate dehydrogenase
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negative ion mode electrospray ionization, one for analysis
by GC–MS, and one sample was reserved for backup.
Samples were placed briefly on a TurboVap (Zymark) to
remove the organic solvent. For LC, the samples were
stored overnight under nitrogen before preparation for
analysis. For GC, each sample was dried under vacuum
overnight before preparation for analysis.
Bioinformatical analyses were performed using the
J-Express (MolMine AS, Bergen, Norway) (Stavrum et al.
2008). For hierarchical clustering all values were median
variance standardized and log(2) transformed. The com-
plete linkage was used as linkage method, and for distance
measured the Pearson correlation was used. Statistical
analyses were performed using the Statistical Package for
the Social Sciences (SPSS) version 15.0 (SPSS Inc., Chi-
cago, IL, USA). The Chi Square test was used to compare
different groups. Unless otherwise stated p values\0.05
were regarded as statistically significant.
3 Results and discussion
3.1 Allotransplant recipients are heterogeneous
with regard to the pretransplant serum
metabolite profile
Our study included 86 consecutive patients. Nine of these
patients (6 men and 3 women, median age 44 years with
range 25–56 years) died from early non-GVHD compli-
cations (i.e. septicemia, organ toxicity) that developed
within 14 days posttransplantation and later progressed to
irreversible multiorgan failure. Seven of these patients had
AML (one secondary to myelodysplastic syndrome); they
were all in first complete remission prior to transplantation
except for one patient who was in second complete
remission. The two last patients had T-ALL and aplastic
anemia, respectively. All patients received myeloablative
conditioning treatment, 7 of them with busulfan plus
cyclophosphamide. Only three of these patients showed
signs of hematopoietic reconstitution at the time of death,
and 8 of them died before day ?25 posttransplant (median
survival 21 days after transplantation, range 7–43 days).
Death due to severe septicemia was seen only for one
patient (pseudomonas aeruginosa, death on day ?7). Thus,
these patients did not differ from the other patients with
regard to these clinical characteristics. The nine patients
were not included in our comparison of patients with and
without acute GVHD because (1) multiorgan failure
developed before acute GVHD would usually be expected,
and (2) the complexity of the clinical situation made it
impossible to diagnose acute GVHD according to generally
accepted criteria but it should be emphasized that none of
the patients showed any of the typical symptoms/signs
consistent with acute GVHD in the skin, liver or gas-
trointestinal tract.
A total of 766 metabolites were analyzed in the pre-
transplant serum samples for all 86 patients (Supplemen-
tary Table 1). These metabolites could be divided into the
eight main categories (corresponding number of metabo-
lites) amino acids (156), peptides (92), carbohydrates (24),
energy metabolism (9), lipids (298), nucleotides (36),
cofactors/vitamins (27) and xenobiotics (124). These
metabolites represent a broad evaluation of the major
metabolic pathways in the cell (Supplementary Table 1).
We first compared the pretransplant metabolic profile of
the 31 patients with and the 46 patients without acute
GVHD; both principal component analysis and hierarchical
clustering then failed to distinguish between these two
patient subsets (data not shown). These observations
probably reflect the metabolic heterogeneity of our patients
when comparing the overall serum metabolite profiles.
3.2 Patients developing acute GVHD have altered
pretransplant levels of several
immunoregulatory metabolites
We then performed a random forest analysis of our patients;
this is a supervised classification statisticalmethod that canbe
used for biomarker identification. By using this method-
ological approach we could identify metabolic biomarkers
that distinguished between patients with and without acute
GVHD with a predictive accuracy of 71.5 % (Fig. 1). This
number is thus greater than the random chance alone
(*50 %), suggesting that the identified metabolites are
candidate biomarkers for predicting risk of GVHD. The fig-
ure shows the top 30 metabolites based on the importance for
the separation of the two groups. A majority of these
metabolites (14 out of 30) are involved in amino acid meta-
bolism, especially the metabolism of immunoregulatory
branched chain amino acids (BCAA), but other
immunomodulatory metabolites were also identified:
• p-cresol sulphate (de Loor et al. 2005) and 3-phenyl-
propionate (Nordlund et al. 2012) are tyrosine deriva-
tives that can be formed by the intestinal bacterial flora
and later be absorbed. p-cresol sulphate seems to have
both proinflammatory and proapoptotic effects (de Loor
et al. 2005).
• Isobutyrylcarnitine and propyonylcarnitine levels were
also altered; the carnitines are important for the
transport of fatty acids and may also be important for
the release of immunoregulatory cytokines in allotrans-
plant recipients (Zatarain and Savani 2012).
• Propionylcarnitine have effects on endothelial cells and
may thereby influence the trafficking of immunocom-
petent cells (Andreozzi 2009; Malaguarnera 2012).
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• Hydantoin-5-propionic acid, the altered level of this
metabolite is consistent with altered metabolism of
valine and/or isoleucine. Furthermore, 3-methyl-
crotonylglycine is formed by the metabolism of BCAAs
and seems to disrupt mitochondrial energy homeostasis
through effects on the respiratory chain, but there is also
altered formation of free radicals (Moura et al. 2012).
Thus, altered pretransplant metabolism of immunoreg-
ulatory amino acids and/or altered pretransplant levels of
immunoregulatory metabolites seem to reflect an increased
risk GVHD.
3.3 Acute GVHD patients show altered
pretransplant metabolism of immunoregulatory
branched chain amino acids
Wealsoperformedanadditional pathway enrichment analysis
based on the number of alteredmetabolites relative to the total
number of all analyzed metabolites in a metabolic pathway;
this was compared with the total number of altered metabo-
lites relative to all the metabolites analyzed. We identified
several metabolic pathways that were enriched in the 31
patients with acute GVHD compared with the 46 patients
without this posttransplant complication (Fig. 2, Supple-
mentaryTable 1), and this alternative analysis showed several
similarities to the previous random forest analysis. Firstly, the
metabolism of branched chain amino acids (i.e. leucine, iso-
leucine and valine) differed between patientswith andwithout
later acute GVHD. Secondly, tyrosine metabolism was also
found to be altered; this observation together with the
observeddifferences in tryptophan, lysine, phenylalanine, and
secondary bile acid metabolism suggest that the pretransplant
gut function/microbiome is altered in patients who develop
acute GVHD (all 86 patients included in the analysis).
Thirdly, tryptophan metabolism can also be important in
immunoregulation, but even though this term was also
increased tryptophan metabolism seems to be less important
for the risk of acute GVHD than BCAA metabolism.
We further analyzed the metabolites belonging to the
top five ranked enriched metabolic pathways: (1) fatty
acid/BCAA metabolism; (2) leucine, isoleucine and
valine metabolism; (3) fatty acid synthesis; (4) guanni-
dino and acetamido metabolism; and (5) inositol
metabolites. We next performed a hierarchical clustering
analysis (Pearson’s Correlation, complete linkage) based
Fig. 1 Random forest analysis of pretransplant metabolite levels;
identification of metabolites showing increased serum levels in
patients with posttransplant acute GVHD. Random forest analysis
could distinguish between the metabolic signatures of patients with
and without acute GVHD with a predictive accuracy of 71.5 %; this
number is higher than random chance alone (*50 %) and suggests
that these metabolites are candidate biomarkers for increased risk of
acute GVHD. The figure presents the top 30 metabolites based on
importance to separate the two patient groups
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on the 44 metabolites that belonged to these five terms
(Fig. 3). There was very little overlap between the five
enriched metabolic pathways, and a major part of these
metabolites were included in the term leucine, isoleucine
and valine metabolism (31 of the 44 metabolites). Based
on the cluster analysis we were able to identify two main
patient clusters; for one cluster 19 out of 34 patients
developed acute GVHD whereas for the other cluster
only 11 out 52 developed GVHD. This difference was
statistically significant (Chi Square test, v2 = 12.69,
p = 0.0004).
We also included the nine patients with early irre-
versible multiorgan failure in the final clustering analysis;
these patients seem to be a heterogeneous subset and the
distribution of these patients did not differ between the
two main subsets. These nine patients also showed a
wide variation in the serum levels of individual
metabolites associated with acute GVHD (Fig. 1) and
with no differences from the other patients. Taken
together these observations suggest that these patients
with early death do not represent a group of patients
dying from hyperacute GVHD. Other causes of multior-
gan failure (i.e. infections, treatment toxicity) seem to be
more likely.
3.4 The metabolic profile associated with an ongoing
pretransplant acute phase reaction differs
from the acute GVHD profile
We then investigated how the pretransplant metabolic
profile differed between patients with and without signs of
ongoing inflammation; we then used the serum level of
C-reactive protein (CRP) as a marker for an acute phase
reaction and compared patients with CRP\ 10 mg/L (no
inflammation, 58 patients) and CRP[ 10 mg/L (with
inflammation, 28 patients). An initial pathway enrichment
analysis identified several metabolic pathways that differed
between these two patient subsets (Fig. 4, Supplementary
Table 1); 15 terms with a pathway enrichment value
exceeding 2 were identified but these terms differed from
the acute GVHD analysis (see above) and did not include
the branched chain amino acid terms. Furthermore, when
doing a random forest analysis the 30 highest ranked
metabolites included only 6 amino acid metabolites, 8 lipid
metabolites were included together with 4 carbohydrates, 5
nucleotides and 7 peptide metabolites. Thus, these
methodological approaches identified other term/metabo-
lites that differed from the acute GVHD-associated profile,
suggesting that the association between metabolic profile
and acute GVHD is not caused by a pretransplant inflam-
mation/acute phase reaction.
We finally performed a hierarchical clustering analysis
based on the results from the analyses (Pearson’s Corre-
lation, complete linkage, Fig. 5). Based on the cluster
analysis we identified two main patient clusters: one main
cluster that included most patients with increased CRP
levels and another including most patients with normal/low
CRP levels; this difference was highly significant (Chi
Square test, v2 = 8.02, p = 0.0046).
3.5 Patients with late hematological reconstitution
have a metabolomic profile characterized
by altered purine and pyrimidine metabolism
None of the patients showed primary graft failure, and we
defined early reconstitution as three consecutive days with
Fig. 2 Pathway enrichment
analysis of metabolic profiles
associated with acute GVHD.
The pathway enrichment
analysis was used to identify
pathways that were altered in
pretransplant samples for
patients with later acute GVHD
compared to patients without
acute GVHD. A pathway
enrichment value greater than 1
indicates that the pathway was
increased in acute GVHD
patients. The top ranked
metabolic pathways (p\ 0.05,
enrichment value[2) identified
by this comparison (GVHD(?)
versus GVHD(-) patients) are
given in the figure
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neutrophil counts [0.2 9 109/L within day ?16 post-
transplant. We also did a pathway enrichment analysis, and
several metabolic pathways were altered when comparing
patients with early reconstitution and late reconstitution
(Supplementary Fig. 2). However, pathways associated
with early reconstitution showed only minor overlap with
GVHD-associated pathways.
3.6 Pretransplant metabolic immunoregulation:
a risk factor for acute GVHD?
The risk of acute GVHD differs between patients and several
pretransplant factors are among the risk factors. Our present
results show that pretransplant levels of immunoregulatory
metabolites reflect a risk of posttransplant acute GVHD.
Our study included a consecutive group of patients with
a family donor from a defined geographic area during a
defined time period. The large majority of patients received
myeloablative conditioning treatment and the same GVHD
prophylaxis, and the guidelines for allotransplantation did
not change during the study period. Thus, the patients
represent a well-defined and relatively homogeneous group
of allotransplant recipients.
As explained above we excluded nine patients who died
early without the classical diagnostic signs of acute GVHD,
but for all except one patient with septicemia the cause of the
multiorgan failure could not be identified. One possible cause
is treatment toxicity, another possibility being hyperacute
GVHD. However, our metabolic studies could not detect any
similarities between these nine patients and the acute GVHD
patients; this makes the last explanation less likely.
Pretransplant characteristics are important for the risk of
posttransplant acute GVHD, e.g. advanced disease, the
conditioning regimens and previous viral infections
(Chaidos et al. 2007; Gratwohl 2012). However, several
studies have investigated the associations between serum
or plasma biomarker levels and the risk of posttransplant
complications, including acute GVHD. Firstly, the risk of
serious complications early after allotransplantation is
associated with the preconditioning serum profile of
Fig. 3 Hierarchical clustering analysis identified two patient subset
highly associated to GVHD. We performed a hierarchical clustering
analysis (Pearsons Correaltion, complete linkage) based on the 44
metabolites included in the top five ranked terms from the pathway
enrichment analysis presented in Fig. 2. Based on the 44 metabolites
belonging to these five terms, we performed a hierarchical clustering
analysis. The heat map and according dendrograms are shown in the
figure. Red indicates high value and green low value, and the five
metabolic pathways can be seen in the left part of the figure. We
identified two main clusters; the left main cluster includes a major
part of patients who later developed acute GVHD, whereas the right
cluster included mainly patients without posttransplant acute GVHD.
The frequency of acute GVHD patients differed significantly between
the clusters (Chi Square test, v2 = 12.69, p = 0.0004)
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immunoregulatory and angioregulatory mediators, and the
same seems to be true for systemic levels of endothelial cell-
derived adhesion molecules (Linda˚s et al. 2014; Reikvam
et al. 2012a). Secondly, an association between serum levels
of angioregulatory Angiopoietin-2/Tie2 and relapse-free
survival was described for a selected group of high-risk
patients with only 17 out of 90 patients being in complete
remission prior to transplantation (Koenecke et al. 2010;
Ku¨mpers et al. 2008). These patients are thus not comparable
to our unselected patients. Thirdly, in a pediatric study Por-
kholm et al. (Porkholm et al. 2013), described that pretrans-
plant (but postconditioning) high Angiopoietin-2 plasma
levels were associated with increased risk of gastrointestinal
GVHD and non-relapse mortality. Thus, our present study is
the first to suggest an association between the precondition-
ing metabolic profile and risk of later acute GVHD.
Tyrosine is synthesized from the essential amino acid
phenylalanine and can be fermented in the gut, one
important product being p-Cresol (de Loor et al. 2005).
Phenols can also be formed by gut fermentation, including
phenyl-propionic acid (Nordlund et al. 2012). A majority
of our patients had acute leukemia in complete remission
and had been treated with intensive antileukemic
chemotherapy prior to the transplantation; this treatment
causes mucositis and may cause severe gastrointestinal
complications (Shafi and Bresalier 2010), and the
production of p-cresols and phenols depends on the
intestinal microenvironment, including intestinal flora and
pH (Nakabayashi et al. 2011). The altered levels of such
metabolites may thus reflect disturbances in the gastroin-
testinal function or the intestinal flora that are associated
with a risk of acute GVHD. These metabolites can origi-
nate from bacterial fermentation in the large intestine (de
Loor et al. 2005; Nordlund et al. 2012); their altered pre-
transplant levels may then predispose to acute GVHD
through effects on donor immunocompetent cells.
p-Cresol is absorbed from the gut and detoxified in the
liver by conjugation (sulfatation and glucuronidation), the
main product in serum being p-cresylsulfate and p-cresyl-
glucuronide (de Loor et al. 2005). However, free p-cresol
can also be detected in the circulation (Bammens et al.
2006; de Loor et al. 2005; Meijers et al. 2010). p-cresyl
sulfate (and also p-cresyl glucuronide) is regarded as a
proinflammatory mediator (Poveda et al. 2014); it activates
leukocyte free radical production, has proapoptotic effects
(Poveda et al. 2014) and alters the endothelial response to
inflammatory cytokines as well as the cytokine release by
monocytes (Schepers et al. 2007). Thus, these metabolites
can possibly alter inflammatory processes both by direct
effects on immunocompetent cells and by altered cell
trafficking/migration due to altered endothelial cell
functions.
Fig. 4 Pathway enrichment
analysis of metabolic profiles
associated with an ongoing
pretransplant acute phase
reaction. The pathway
enrichment analysis was used to
identify metabolites/pathways
that were altered in
pretransplant samples derived
from patients with an ongoing
pretransplant acute phase
reaction (i.e. serum
CRP[ 10 mg/L) compared to
patients with normal CRP level.
A pathway enrichment value
greater than 1 indicates that the
pathway was increased in
patients with an acute phase
reaction. The top ranked
metabolic pathways (p\ 0.05,
enrichment value[2) identified
by this comparison are given in
the figure
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Carnitine is an essential dietary nutrient and it acts as a
carrier of fatty acids across the inner membrane of the
mitochondrial membrane (Malaguarnera 2012). Oral propy-
onyl-L-carnitine has been tried in the treatment of human
diseases (Andreozzi 2009; Malaguarnera 2012), mainly car-
diovascular disease, but it has also shown beneficial effects in
a randomized, double-blind, placebo-controlled study of
patients with ulcerative colitis, i.e. an autoimmune disease
(Mikhailova et al. 2011). The vascular effects of propyonyl-
L-isocarnitine include reduced plasma extravasation, modu-
lation of endothelin-prostaglandin effects, vasodilatation,
and increased fatty acid oxidation in vascular tissue. These
effects may then affect the trafficking of immunocompetent
cells and thereby also the risk of acute GVHD.
Both in vitro and in vivo studies suggest that the bran-
ched chain amino acids have immunoregulatory effects that
at least partly are mediated through mTOR activation (Kim
et al. 2012). Firstly, leucine has been shown to increase the
release of leptin in animal models (Lynch et al. 2006),
another important metabolic immunoregulator (Agrawal
et al. 2011). Secondly, especially valine seems important
for the differentiation of normal monocytes to specialized
and mature antigen-presenting dendritic cells, and this
differentiation is then associated with a PI3K-Akt-mTOR
induced metabolic switch to glycolysis (Kakazu et al.
2007). Finally, both leucine, isoleucine or valine seem to
enhance the proliferation of activated T cells (Calder
2006), and animal studies suggest that oral intake of iso-
leucine has an immunoregulatory function in the gut (Zhao
et al. 2014). Finally, several studies suggest that BCAA
have immunostimulatory effects not only in animal models
but also in humans (Alam et al. 2011; Bassit et al. 2002;
Cerra et al. 1984; Freund et al. 1978; Nuwer et al. 1983).
Thus, our study suggests that the pretransplant status of the
immunoregulatory system is important for the risk of
posttransplant acute GVHD.
We also analysed the metabolites associated with a
pretransplant acute phase reaction (i.e. increased serum
CRP levels), but the metabolic terms as well as individual
metabolites associated with increased CRP levels differed
Fig. 5 Hierarchical clustering analysis identified two patient subset
highly associated with pretransplant inflammation. The hierarchical
clustering analysis (Pearsons Correaltion, complete linkage) was
based on the 64 metabolites that belonged to the 11 terms/those
metabolic pathways showing enrichment score[3.0 and p\ 0.001.
The heat map together with dendrograms is presented in the figure.
Red indicates high value and green low value, and the metabolic
pathways are shown to the left. We identified two main clusters; one
including several patients with an acute phase reaction (left) and
another including few of these patients (right). These two main
clusters differed significantly with regard to the frequency of
pretransplantation inflammation processes (Chi Square test,
v2 = 8.02, p = 0.0046)
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from the terms/metabolites associated with acute GVHD.
The same was true for terms/metabolites associated with
early hematopoietic reconstitution. These observations
suggest that the metabolic mechanisms associated with the
risk of acute GVHD are independent of the acute phase
reaction and bone marrow recovery.
4 Concluding remarks
Our present study suggests that the pretransplant metabolic
profile reflects the risk of developing acute GVHD after
allotransplantation. Several of the metabolites or the
metabolic pathways that were observed to reflect this risk
(tyrosine metabolites, BCAAs, fatty acid metabolism), are
important for immunoregulation and may thus be directly
involved in the development of acute GVHD through
effects on donor immunocompetent cells. The question
whether pretransplant metabolic interventions (i.e. nutri-
tional support) will decrease the risk of posttransplant acute
GVHD has to be addressed in future clinical studies.
Compliance with ethical standards
Conflict of Interest All authors declare that they have no conflicts
of interest related to this manuscript.
Ethical approval All procedures performed in studies involving
human participants were in accordance with the ethical standards of
the institutional and/or national research committee and with the 1964
Helsinki declaration and its later amendments or comparable ethical
standards.
Funding The study was supported by Øyvinn Mølbach-Pedersen’s
foundation, Helse Vest and the Norwegian Cancer Society.
Informed consent Informed consent was obtained from all indi-
vidual participants included in the study.
References
Agrawal, S., Gollapudi, S., Su, H., & Gupta, S. (2011). Leptin
activates human B cells to secrete TNF-alpha, IL-6, and IL-10
via JAK2/STAT3 and p38MAPK/ERK1/2 signaling pathway.
Journal of Clinical Immunology, 31, 472–478. doi:10.1007/
s10875-010-9507-1.
Alam, N. H., et al. (2011). L-isoleucine-supplemented oral rehydra-
tion solution in the treatment of acute diarrhoea in children: A
randomized controlled trial. Journal of Health, Population, and
Nutrition, 29, 183–190.
Andreozzi, G. M. (2009). Propionyl l-carnitine: Intermittent claudi-
cation and peripheral arterial disease. Expert Opinion on
Pharmacotherapy, 10, 2697–2707. doi:10.1517/
14656560903215871.
Bammens, B., Evenepoel, P., Keuleers, H., Verbeke, K., & Van-
renterghem, Y. (2006). Free serum concentrations of the protein-
bound retention solute p-cresol predict mortality in hemodialysis
patients. Kidney International, 69, 1081–1087. doi:10.1038/sj.ki.
5000115.
Bassit, R. A., et al. (2002). Branched-chain amino acid supplemen-
tation and the immune response of long-distance athletes.
Nutrition, 18, 376–379.
Calder, P. C. (2006). Branched-chain amino acids and immunity.
Journal of Nutrition, 136, 288S–293S.
Cerra, F. B., et al. (1984). Branched chain metabolic support. A
prospective, randomized, double-blind trial in surgical stress.
Annals of Surgery, 199, 286–291.
Chaidos, A., Kanfer, E., & Apperley, J. F. (2007). Risk assessment in
haemotopoietic stem cell transplantation: Disease and disease
stage. Best Practice & Research Clinical Haematology, 20,
125–154. doi:10.1016/j.beha.2006.10.003.
Chen, W. L., et al. (2014). A distinct glucose metabolism signature of
acute myeloid leukemia with prognostic value. Blood,. doi:10.
1182/blood-2014-02-554204.
de Loor, H., Bammens, B., Evenepoel, P., De Preter, V., & Verbeke,
K. (2005). Gas chromatographic-mass spectrometric analysis for
measurement of p-cresol and its conjugated metabolites in
uremic and normal serum. Clinical Chemistry, 51, 1535–1538.
doi:10.1373/clinchem.2005.050781.
Evans, A. M., et al. (2014). High resolution mass spectrometry
improves data quanitity and quality as compared to unit mass
resolution mass spectrometry in high-throghput profiling meta-
bolomics. Metabolomics, 4, 132.
Filipovich, A. H. (2008). Diagnosis and manifestations of chronic
graft-versus-host disease. Best Practice & Research Clinical
Haematology, 21, 251–257. doi:10.1016/j.beha.2008.02.008.
Freund, H. R., Ryan, J. A, Jr, & Fischer, J. E. (1978). Amino acid
derangements in patients with sepsis: Treatment with branched
chain amino acid rich infusions. Annals of Surgery, 188, 423–430.
Gooley, T. A., et al. (2010). Reduced mortality after allogeneic
hematopoietic-cell transplantation. New England Journal of
Medicine, 363, 2091–2101. doi:10.1056/NEJMoa1004383.
Gratwohl, A. (2012). The EBMT risk score. Bone Marrow Trans-
plantation, 47, 749–756. doi:10.1038/bmt.2011.110.
Kakazu, E., Kanno, N., Ueno, Y., & Shimosegawa, T. (2007).
Extracellular branched-chain amino acids, especially valine,
regulate maturation and function of monocyte-derived dendritic
cells. The Journal of Immunology, 179, 7137–7146.
Kersey, J. H. (2010). The role of allogeneic-cell transplantation in
leukemia. New England Journal of Medicine, 363, 2158–2159.
doi:10.1056/NEJMe1010818.
Kim, Y. M., et al. (2012). SH3BP4 is a negative regulator of amino
acid-Rag GTPase-mTORC1 signaling. Molecular Cell, 46,
833–846. doi:10.1016/j.molcel.2012.04.007.
Koenecke, C., et al. (2010). Shedding of the endothelial receptor
tyrosine kinase Tie2 correlates with leukemic blast burden and
outcome after allogeneic hematopoietic stem cell transplantation
for AML. Annals of Hematology, 89, 459–467. doi:10.1007/
s00277-009-0869-5.
Ku¨mpers, P., et al. (2008). Angiopoietin-2 predicts disease-free
survival after allogeneic stem cell transplantation in patients with
high-risk myeloid malignancies. Blood, 112, 2139–2148. doi:10.
1182/blood-2007-12-130021.
Linda˚s, R., Tvedt, T. H., Hatfield, K. J., Reikvam, H., & Bruserud, O.
(2014). Preconditioning serum levels of endothelial cell-derived
molecules and the risk of posttransplant complications in
patients treated with allogeneic stem cell transplantation. Journal
of transplantation, 2014, 404096. doi:10.1155/2014/404096.
Lynch, C. J., Gern, B., Lloyd, C., Hutson, S. M., Eicher, R., & Vary,
T. C. (2006). Leucine in food mediates some of the postprandial
rise in plasma leptin concentrations. American Journal of
Physiology-Endocrinology and Metabolism, 291, E621–E630.
doi:10.1152/ajpendo.00462.2005.
12 Page 10 of 11 H. Reikvam et al.
123
Malaguarnera, M. (2012). Carnitine derivatives: Clinical usefulness.
Current Opinion in Gastroenterology, 28, 166–176. doi:10.1097/
MOG.0b013e3283505a3b.
Meijers, B. K., et al. (2010). p-Cresol and cardiovascular risk in mild-
to-moderate kidney disease. Clinical Journal of the American
Society of Nephrology, 5, 1182–1189. doi:10.2215/CJN.
07971109.
Mikhailova, T. L., et al. (2011). Randomised clinical trial: The
efficacy and safety of propionyl-L-carnitine therapy in patients
with ulcerative colitis receiving stable oral treatment. Alimentary
Pharmacology & Therapeutics, 34, 1088–1097. doi:10.1111/j.
1365-2036.2011.04844.x.
Moura, A. P., Ribeiro, C. A., Zanatta, A., Busanello, E. N., Tonin, A.
M., & Wajner, M. (2012). 3-Methylcrotonylglycine disrupts
mitochondrial energy homeostasis and inhibits synaptic Na(?),
K (?)-ATPase activity in brain of young rats. Cellular and
Molecular Neurobiology, 32, 297–307. doi:10.1007/s10571-011-
9761-7.
Nakabayashi, I., et al. (2011). Effects of synbiotic treatment on serum
level of p-cresol in haemodialysis patients: A preliminary study.
Nephrology Dialysis Transplantation, 26, 1094–1098. doi:10.
1093/ndt/gfq624.
Nordlund, E., Aura, A. M., Mattila, I., Kosso, T., Rouau, X., &
Poutanen, K. (2012). Formation of phenolic microbial metabo-
lites and short-chain fatty acids from rye, wheat, and oat bran
and their fractions in the metabolical in vitro colon model.
Journal of Agricultural and Food Chemistry, 60, 8134–8145.
doi:10.1021/jf3008037.
Nuwer, N., Cerra, F. B., Shronts, E. P., Lysne, J., Teasley, K. M., &
Konstantinides, F. N. (1983). Does modified amino acid total
parenteral nutrition alter immune-response in high level surgical
stress. JPEN. Journal of Parenteral and Enteral Nutrition, 7,
521–524.
Porkholm, M., Bono, P., Saarinen-Pihkala, U. M., & Kivivuori, S. M.
(2013). Higher angiopoietin-2 and VEGF levels predict shorter
EFS and increased non-relapse mortality after pediatric
hematopoietic SCT. Bone Marrow Transplantation, 48, 50–55.
doi:10.1038/bmt.2012.101.
Poveda, J., et al. (2014). p-cresyl sulphate has pro-inflammatory and
cytotoxic actions on human proximal tubular epithelial cells.
Nephrology Dialysis Transplantation, 29, 56–64. doi:10.1093/
ndt/gft367.
Reikvam, H., Fredly, H., Kittang, A. O., & Bruserud, O. (2013). The
possible diagnostic and prognostic use of systemic chemokine
profiles in clinical medicine-the experience in acute myeloid
leukemia from disease development and diagnosis via conven-
tional chemotherapy to allogeneic stem cell transplantation.
Toxins, 5, 336–362. doi:10.3390/toxins5020336.
Reikvam, H., Hatfield, K. J., Fredly, H., Nepstad, I., Mosevoll, K. A.,
& Bruserud, O. (2012a). The angioregulatory cytokine network
in human acute myeloid leukemia—From leukemogenesis via
remission induction to stem cell transplantation. European
Cytokine Network, 23, 140–153. doi:10.1684/ecn.2012.0322.
Reikvam, H., et al. (2012b). The pretransplantation serum cytokine
profile in allogeneic stem cell recipients differs from healthy
individuals, and various profiles are associated with different
risks of posttransplantation complications. Biology of Blood and
Marrow Transplantation, 18, 190–199. doi:10.1016/j.bbmt.2011.
10.007.
Schepers, E., Meert, N., Glorieux, G., Goeman, J., Van der Eycken, J.,
& Vanholder, R. (2007). P-cresylsulphate, the main in vivo
metabolite of p-cresol, activates leucocyte free radical produc-
tion. Nephrology Dialysis Transplantation, 22, 592–596. doi:10.
1093/ndt/gfl584.
Servais, S., et al. (2014). Pre-transplant prognostic factors of long-
term survival after allogeneic peripheral blood stem cell
transplantation with matched related/unrelated donors. Haema-
tologica, 99, 519–526. doi:10.3324/haematol.2013.089979.
Shafi, M. A., & Bresalier, R. S. (2010). The gastrointestinal
complications of oncologic therapy. Gastroenterology Clinics
of North America, 39, 629–647. doi:10.1016/j.gtc.2010.08.004.
Sorror, M. (2009). Impacts of pretransplant comorbidities on
allogeneic hematopoietic cell transplantation (HCT) outcomes.
Biology of Blood and Marrow Transplantation, 15, 149–153.
doi:10.1016/j.bbmt.2008.12.498.
Stavrum, A. K., Petersen, K., Jonassen, I., Dysvik, B. (2008).
Analysis of gene-expression data using J-Express. Curr Protoc
Bioinformatics Chapter 7, Unit 7 3 doi:10.1002/0471250953.
bi0703s21.
Tvedt, T. H., Reikvam, H., Bruserud, O. (2016). Nutrition in allogenic
stem cell transplantation—Clinical guidelines and immunobio-
logical aspects. Current Pharmaceutical Biotechnology, 17,
92–104. doi:10.2174/138920101701151027163600.
Wang, J. H., et al. (2013). Prognostic significance of 2-hydroxyglu-
tarate levels in acute myeloid leukemia in China. Proc Natl Acad
Sci USA, 110, 17017–17022. doi:10.1073/pnas.1315558110.
Zatarain, L., & Savani, B. N. (2012). The role of nutrition and effects
on the cytokine milieu in allogeneic hematopoietic stem cell
transplantation. Cellular Immunology, 276, 6–9. doi:10.1016/j.
cellimm.2012.05.003.
Zhao, J., et al. (2014). Effect of dietary isoleucine on the immunity,
antioxidant status, tight junctions and microflora in the intestine
of juvenile Jian carp (Cyprinus carpio var. Jian). Fish & Shellfish
Immunology, 41, 663–673. doi:10.1016/j.fsi.2014.10.002.
The pretransplant systemic metabolic profile reflects a risk of acute graft versus host… Page 11 of 11 12
123
